- Home
- FGNX vs PRPO Comparison
FGNX vs PRPO Comparison
Compare FGNX & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | PRPO |
|---|---|---|
| Founded | 1932 | N/A |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 44.4M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | FGNX | PRPO |
|---|---|---|
| Price | $5.03 | $24.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $36.50 | N/A |
| AVG Volume (30 Days) | ★ 62.6K | 10.2K |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $18,532,000.00 |
| Revenue This Year | $95.83 | N/A |
| Revenue Next Year | $42.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $1.59 | $4.90 |
| 52 Week High | $18.42 | $29.53 |
Technical Indicators
Market Signals| Indicator | FGNX | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 41.10 |
| Support Level | $2.48 | $22.58 |
| Resistance Level | $6.36 | $26.16 |
| Average True Range (ATR) | 0.43 | 1.53 |
| MACD | -0.32 | -0.43 |
| Stochastic Oscillator | 1.09 | 0.00 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.